The radiolabelled compound 212Pb-TCMC-trastuzumab shows promising pre-clinical anti-tumour activity, binding to the extracellular domain of human epidermal growth factor receptor 2 (HER2). The gene discussed is ERBB2; the disease is neoplasm.